Loading…
Jiangxi TCM maker best known for Jianwei Xiaoshi Pian, a widely sold digestive-aid tablet, under the China Resources group.
Jiangxi TCM maker best known for Jianwei Xiaoshi Pian, a widely sold digestive-aid tablet, under the China Resources group.
Relies on one over-the-counter tablet for much of its revenue and spends heavily on advertising and pharmacy-chain promotion to keep it in front of shoppers, so marketing outlay and a single brand's fortunes shape results. Sold mainly through pharmacy chains and distributors.
In one line: A Chinese TCM digestive-remedy maker (like a herbal Tums).
Moat: narrow (brand, distribution). Long-established OTC digestive brand with China Resources group distribution support.
Headquarters: Nanchang, Jiangxi, China · Employees: 4,352
Size China Resources Jiangzhong Pharmaceutical (600750.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.19B, the 1163rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥23.21 on 6 Nov 2026.
Performance Over six months the shares fell 3.0%, against -1.5% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 10.2% over the last twelve months (peer median +10.2%); the operating margin is 23.6% (peer median 15.5%).
Valuation It trades at 15.7× forward earnings against a peer median of 18.3× (8th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.95B | CN¥4.18B | CN¥4.40B | CN¥4.52B | CN¥3.85B |
| Revenue growth | — | -5% | -3% | +17% | — |
| Gross profit | CN¥2.65B | CN¥2.67B | CN¥2.73B | CN¥2.82B | CN¥2.42B |
| EBITDA | n/a | CN¥1.17B | CN¥1.03B | CN¥966M | CN¥744M |
| Net income | CN¥841M | CN¥907M | CN¥788M | CN¥719M | CN¥598M |
| Free cash flow | CN¥891M | CN¥738M | CN¥569M | CN¥870M | CN¥730M |
| Capital expenditure | CN¥229M | CN¥281M | CN¥291M | CN¥211M | CN¥346M |
| Total debt | CN¥637M | CN¥355M | CN¥6.29M | CN¥56.6M | CN¥89.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% |
| Chongqing Taiji Industry (Group) 600129.SS | $1.09B | -15% | -4% | 2% | 26.5× | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600750.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.7% | +0.5% | 10th highest of 21 |
| 6-month return | -3.0% | -1.5% | 10th lowest of 21 |
| Distance from 52-week high | -16.6% | -20.8% | 9th highest of 21 |
| Revenue growth (TTM) | -10.2% | +10.2% | 2nd lowest of 21 |
| Operating margin | 23.6% | 15.5% | 7th highest of 21 |
| Forward P/E | 15.7× | 18.3× | 8th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -2.5% | 2.1% | 6th least demanding of 20 |
| Growth delivered (Del g) | +11.6% | +5.9% | 6th highest of 20 |
| Hurdle (Req g minus delivered) | -14.1 pp | -7.3 pp | 6th least demanding of 20 |
| ROIC minus cost of capital | +10.3 pp | +2.7 pp | 6th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% | +5.3% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% | +0.6% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | n/a | 5.2% | +1.0% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 1.9× | -14.5% | +5.9% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 80.3× | 34.7% | +5.9% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% | -2.2% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |